VitaNova Life Sciences Corporation
VNOV
$4.83
-$2.67-35.60%
OTC PK
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.19M | 2.79M | 2.66M | 2.66M | 1.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.19M | 2.79M | 2.66M | 2.66M | 1.25M |
| Cost of Revenue | 1.39M | 1.12M | 1.09M | 1.09M | 483.60K |
| Gross Profit | 1.80M | 1.68M | 1.57M | 1.58M | 769.90K |
| SG&A Expenses | 607.50K | 418.30K | 349.90K | 367.30K | 411.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.00M | 1.53M | 1.44M | 1.45M | 894.70K |
| Operating Income | 1.20M | 1.26M | 1.22M | 1.21M | 358.80K |
| Income Before Tax | 1.19M | 1.26M | 1.22M | 1.20M | 356.50K |
| Income Tax Expenses | 448.90K | 393.10K | 357.70K | 353.60K | 138.10K |
| Earnings from Continuing Operations | 0.75 | 0.86 | 0.86 | 0.85 | 0.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 745.40K | 862.80K | 859.60K | 850.70K | 218.30K |
| EBIT | 1.20M | 1.26M | 1.22M | 1.21M | 358.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.09 | 0.10 | 0.10 | 0.10 | 0.03 |
| Normalized Basic EPS | 0.09 | 0.09 | 0.09 | 0.09 | 0.03 |
| EPS Diluted | 0.09 | 0.10 | 0.10 | 0.10 | 0.03 |
| Normalized Diluted EPS | 0.09 | 0.09 | 0.09 | 0.09 | 0.03 |
| Average Basic Shares Outstanding | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M |
| Average Diluted Shares Outstanding | 33.35M | 33.35M | 33.35M | 33.35M | 33.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |